Drugs / VL-P22
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05387239 | Nov 2022 → Nov 2024 | COVID-19, pulmonary fibrosis | Vitti Labs, LLC | Suspended | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VL-P22 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05387239 ↗ |
| Route | Intravenous | “intravenous infusion of VL-PX10 and VL-P22” NCT05387239 ↗ |